Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? by Bronte G. et al.
Research Article
Evaluation of Androgen Receptor in Relation to
Estrogen Receptor (AR/ER) and Progesterone Receptor
(AR/PgR): A New Must in Breast Cancer?
Giuseppe Bronte,1 Andrea Rocca ,1 Sara Ravaioli ,1 Emanuela Scarpi ,1
Massimiliano Bonafè,1,2 Maurizio Puccetti,3 Roberta Maltoni,1 Daniele Andreis,1
Giovanni Martinelli,1 and Sara Bravaccini 1
1 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
2Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy
3AUSL (Azienda Unita` Sanitaria Locale) Imola, Imola, Italy
Correspondence should be addressed to Sara Ravaioli; sara.ravaioli@irst.emr.it
Received 21 January 2019; Accepted 17 March 2019; Published 14 April 2019
Guest Editor: Daniele Vergara
Copyright © 2019 Giuseppe Bronte et al.This is an open access article distributed under theCreativeCommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Steroid nuclear receptors are known to be involved in the regulation of epithelial-mesenchymal transition process with important
roles in invasion and metastasis initiation. Androgen receptor (AR) has been extensively studied, but its role in relation to breast
cancer patient prognosis remains to be clarified. AR/ER ratio has been reported to be an unfavorable prognostic marker in early
primary breast cancer, but its role in the patients with advanced disease has to be cleared. We retrospectively analyzed ER, PgR,
and AR expression on a case series of 159 specimens of primary BC samples by using immunohistochemistry and 89 patients of
these had luminal tumors for which AR and ER expression and survival data were available. For twenty-four patients both primary
and metastatic tumors were available. A significantly shorter overall survival was observed in primary tumors with AR/PgR ratio
≥ 1.54 (HR = 2.27; 95% CI 1.30-3.97; p = 0.004). Similarly OS was significantly shorter when ER/PgR ratio ≥2 in primary tumors
(HR = 1.89; 95% CI 1.10-3.24; p = 0.021).The analysis of the 24 patients who had biomarker determinations both in primary tumors
and metastasis showed a better OS when AR/ER ratio in the metastasis was ≥ 0.90 (p = 0.022). Patients with a high AR/ER ratio in
primary tumor that remained high in the metastasis had better prognosis in terms of OS (p = 0.011). Despite we suggested that the
ratios AR/ER and AR/PgR could be used to identify patients with different prognosis, their real value needs to be better clarified in
different BC settings through prospective studies.
1. Introduction
Steroid nuclear receptors are known to have an important role
in the regulation of epithelial-mesenchymal transition (EMT)
process and in the tumor progression [1].
Beyond specific EMT-inducing factors such as Snail and
Slug, a “multiverse” of factors, including hormone receptor
signaling pathways are involved in metastasis establishment
regulating cell plasticity and motility [2]. Given that EMT
transcription studies in breast cancer mainly focus on triple
negative breast cancer (BC) subtype BRCA1 addicted, more
information is needed in luminal cancers [3].
Androgen receptor (AR) may have EMT promoting
effects through the suppression of E-cadherin promoter
activated by dihydrotestosterone. This is in contrast with the
fact that AR expression is associated with a good prognosis
suggesting a tumor and EMT-suppressing effects [1].
The possibility that a receptor for androgen is expressed
in BC is fascinating given that the tumor is predominantly
estrogen-dependent.
Although the AR has been extensively studied, its role
in this malignancy remains to be clarified as well as its
relation with the other steroid nuclear receptor involved in
BC biology, such as estrogen receptor (ER) or progesterone
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receptor (PgR). Researchers are currently trying to under-
stand whether AR interferes with ER or PgR activity. AR
is already a therapeutic target, and the availability of selec-
tive AR inhibitors (e.g., bicalutamide, enzalutamide, apalu-
tamide) approved for the treatment of prostate cancer has
opened up the possibility of their use in BC patients whose
tumors express AR. However, things are not as simple as they
seem as AR appears to have different functions according to
the BC subtype, e.g., ER positive or triple negative BC. In ER-
negative BC, studies on the prognostic effect of AR expression
yielded conflicting results [4, 5] even though AR can predict
response to AR inhibitors [6]. Conversely, patients with ER
positive and AR positive have a better outcome than those
with ER positive and AR-negative disease [4, 7]. This has
been attributed to the competition between AR and ER at the
level of estrogen response elements (EREs) and consequent
impairment of ER-dependent gene transcription [8].
A few years ago Cochrane et al. reported a worse progno-
sis when AR levels were high and ER levels were low, which
resulted in a resistance to tamoxifen.The authors defined the
relationship between AR and ER expression as the AR/ER
ratio. They had been prompted to perform this study by the
observation that, while BC is well differentiated and more
indolent when AR is expressed, AR overexpression leads to
tamoxifen resistance in in vitro and in vivo studies. This
study can be considered a seminal work because the authors
introduce the concept of the AR/ER ratio for the first time.
This new parameter could be useful in ER positive BC as the
majority of these tumors (84-91%) areARpositive. Hence, the
simple evaluation of AR expression may not be sufficient to
further subdivide the ER positive subset into different prog-
nostic groups. Cochrane et al. identified 2.0 as the best AR/ER
cut-off value to classify patients according to disease-free
survival (DFS). In their study of around 200 patients with pri-
mary BC, an AR/ER ratio ≥ 2.0 identified a subgroup with a
four-fold higher risk of failure during adjuvant tamoxifen [9].
More recently, Rangel et al. explored the usefulness
of the AR/ER ratio in a larger population of ER+/HER2-
BC patients. A higher AR/ER ratio was associated with
unfavorable features (e.g., larger primary tumor, higher nodal
status, higher histological grading). Like Cochrane et al.,
the authors identified 2.0 as the best cut-off to distinguish
between prognostic cohorts. Thus, an AR/ER ≥ 2.0 predicted
poor survival in primaryBCpatients in terms of both disease-
free interval (five-fold higher risk of relapse) and disease-
specific survival (> eight-fold higher risk of relapse) [10].
The results from the above 2 studies in which the AR/ER
ratio was used to estimate prognosis in patients with primary
luminal BC (i.e., ER+/HER2-) raises the question as to
whether this new parameter will become mandatory for
prognostic classification in this BC subset. We previously
showed that the AR/PgR ratio, but not the AR/ER ratio or
AR expression alone, plays a prognostic role in metastatic BC
patients who are treated with antiestrogen therapy [11]. We
can contribute to the debate on the prognostic role of the ratio
through a study assessing not only the AR/ER ratio, but also
the AR/PgR and ER/PgR ratios in a subset of patients with
disease progression where the meaning of these ratios have
never been explored.
2. Methods
2.1. Case Series. For the present work we retrospectively
analyzed a case series of patients consecutively enrolled from
2000 to 2008 at the Breast Unit of Morgagni-Pierantoni
Hospital in Forl`ı. Eligible criteria were ≥18 years old, his-
tological diagnosis of invasive BC, and a follow-up of at
least 5 years. All patients had to have experienced distant
disease relapse/progression. At least one specimen from the
primary tumor and/or one from a metastasis had to be
available for patients to be considered. The total number
of patients analyzed was 159; primary tumor samples were
available for all patients, while 24 had also a metastatic
sample. All patients had to have hormone receptor expression
data available.The Ethics Committee of IRST and AVR (Area
Vasta Romagna) reviewed and approved the study protocol
and patients provided written informed consent according to
Italian privacy law.
2.2. Immunohistochemistry. The original hematoxylin and
eosin stained specimens were reviewed by an expert patholo-
gist to identify themost representative inclusion of tumor tis-
sue for each patient. Neutral buffered formalin was used to fix
tumor material obtained during surgery. Paraffin-embedded
sections (four-micron thickness) were mounted on positive-
charged slides for each sample (Bio Optica, Milan, Italy).
Biomarker determinations were performed according to
EuropeanQuality Assurance guidelines. Immunostaining for
conventional biomarkers and AR expression was performed
using the Ventana Benchmark XT staining system (Ventana
Medical Systems, Tucson, AZ, USA) with the Optiview DAB
Detection Kit (Ventana Medical Systems). ER, PgR, (Leica,
Novocastra, Newcastle, UK), and AR (SP107 Cell Marque,
Ventana Medical Systems) antibodies were used. For ER
and PgR assessment, tissue sections were incubated for 60
minutes with antibodies diluted 1:80 and 1:40, respectively, in
antibody diluents (Ventana Medical Systems). AR antibody,
prediluted by the supplier, was used. Finally, all the sections
were automatically counterstained for 16 minutes with hema-
toxylin II (Ventana Medical Systems). Biomarker expression
was detected and semiquantitatively quantified as the per-
centage of immunopositive tumor cells on the total of tumor
cells. Two independent observers evaluated all the samples
and a discordance of >10% of positive cells was resolved by
consensus after joint review using a multihead microscope.
As clear guidelines for AR expression have not been available
until now, we have not used a cut-off value. Given that
we aimed to calculate the AR/ER and AR/PgR ratios, AR
expression value was considered as a continuous variable
(percentage of immunopositive tumor cells ranging 0-100%)
and not dichotomous (positive/negative). As reported in our
previous work, when ER or PgR were negative, the AR value
was used instead of AR/ER and AR/PgR values [12].
2.3. Statistical Analysis. Overall survival (OS) was calcu-
lated as the time from the date of the start of first-
line treatment for metastatic disease to the date of death
from any cause or the date of the last follow-up visit.
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OS was estimated using the Kaplan-Meier method and
compared with the log-rank test. Hazard ratios (HRs) and
95% confidence intervals (95% CI) were calculated using
the Cox regression model. The optimal cut-off values were
obtained from receiver operating characteristic (ROC) curve
analysis at a median OS of 63 months. The concordance
rate was calculated as the proportion of concordant cases
with respect to the total number of patients. The two-
sided exact binomial 95% confidence interval (95% CI) was
estimated. All p values were based on two-sided testing
and statistical analyses were performed using SAS statistical
software version 9.4 (SAS Inc., Cary, NC, United States of
America).
3. Results
We considered 159 BC patients with available primary tumor
samples and data on AR and ER expression, of whom 125
patients had luminal tumor (defined as ER ≥1% and/or
PgR ≥1% with any Ki67 or HER2 values). In order to
calculate ratios we considered the 113 patients with AR and
ER both ≥1%. Of these, survival data were available for 89
patients for whom we performed OS analyses. The patients’
characteristics are reported in Table 1.
The median AR/ER ratio of the primary tumors in the
luminal case series was 0.95 (range 0.06-95.00) while the
median AR/PgR and ER/PgR ratios were 1.55 (range 0.06-
95.00) and 1.60 (range 0.08-90.00) respectively (Table 2).The
optimal cut-off values for AR/ER, AR/PgR, ER/PgR ratios
to stratify patients according to prognosis were 0.95, 1.54,
and 2, respectively. These values were obtained from receiver
operating characteristic (ROC) curve analysis at amedianOS
of 63 months.
We evaluated the impact of the AR/ER, AR/PgR, ER/PgR
ratios on OS. Hazard ratios (HRs) and 95% confidence
intervals (95% CI) were calculated using the Cox regression
model.
Median OS was longer for patients with AR/ER values <
0.95 (p value not significant) in primary tumors (Table 2).
OS was significantly shorter when the AR/PgR ratio was
≥ 1.54 for primary tumors (HR = 2.27; 95% CI 1.30-3.97; p =
0.004) (Table 2).
Similar results were obtained for ER/PgR ratio ≥ 2 in
primary tumors where OS was significantly shorter (HR =
1.89; 95% CI 1.10-3.24; p = 0.021) (Table 2).
OS was better when AR/ER in the metastasis was ≥
0.90 (HR = 0.09; 95% CI 0.01-0.70; p = 0.022) (Table 3). In
addition, we assessed whether the difference in the AR/ER
and AR/PgR ratios between primary tumor and metastasis
influenced prognosis (Table 3).
Patients with a high AR/ER ratio in primary tumor that
remained high in themetastasis had better prognosis in terms
of OS (p = 0.011) (Table 3).
Analysis of the AR/ER ratio showed a concordance
between primary tumors and metastases of 45.83% (95% CI
25.90-65.76) using 0.90 as cut-off value, whereas a concor-
dance of 41.67% (95% CI 21.95-61.39) was observed for the
AR/PgR ratio when the cut-off value was set at 0.96.
Table 1: Patients’ characteristics.
No. (%)
Total number 159 pts
Age
<50 40 (25.2)
≥50 119 (74.8)
Tumor samples
Primary 159 (100)
Metastasis 24 (15.1)
Both 24 (15.1)
T at diagnosis
1 73 (50.0)
2 56 (38.4)
3 5 (3.4)
4 12 (8.2)
Unknown 13
N at diagnosis
0 59 (41.8)
1 52 (36.9)
2 14 (9.9)
3 16 (11.4)
Unknown 18
M at diagnosis
0 122 (76.7)
1 37 (23.3)
Grade
1 6 (4.8)
2 48 (38.1)
3 72 (57.1)
Unknown 33
Adjuvant systemic therapy
No adjuvant therapy 12 (7.5)
Chemotherapy 84 (52.8)
Hormone therapy 84 (52.8)
Both 58 (36.5)
Unknown 37 (23.3)
We report the immunohistochemical images of one
patient for whom both primary tumor and metastasis
specimens stained for AR, ER, and PgR were available. The
AR/ER, AR/PgR, and ER/PgR ratios were calculated in each
specimen to underline how they can change in different
lesions from the same patient (Figure 1).
Another evaluation was done on the complete case series
of 159 patients with any (positive or negative) values for ER,
PgR, and AR. Of these, 104 patients had data on survival.
Median ratios of AR/ER, AR/PgR, and ER/PgR were 0.95,
1.59, and 1.35, respectively (Table 4). OS was shorter when the
ER/PgR ratio was ≥ 2 in primary tumors (HR= 1.90; 95% CI
1.14-3.17; p=0.014). AR/ER andAR/PgR ratios did not predict
OS (Table 4).
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Table 2: Impact of AR/ER, AR/PgR, and ER/PgR ratios on OS in primary tumors of luminal BC patients (no. 89).
Median ratios (range)
AR/ER 0.95 (0.06 - 95.00)
AR/PgR 1.55 (0.06 - 95.00)
ER/PgR 1.60 (0.08 - 90.00)
OS according to best cut-off ratio
Median follow-up: 78 months (range 7 - 155)
no. deaths/no. patients Median OS (months)(95% CI)
HR
(95% CI) p
Overall 55/89 63 (46-76) - -
AR/ER
<0.95 28/47 64 (41-82) 1.00
≥0.95 27/42 60 (42-83) 1.05 (0.62-1.78) 0.861
AR/PgR
<1.54 21/39 82 (65-89) 1.00
≥1.54 34/50 42 (34-56) 2.27 (1.30-3.97) 0.004
ER/PgR
<2.00 25/40 82 (62-88) 1.00
≥2.00 30/49 42 (34-64) 1.89 (1.10-3.24) 0.021
AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor;OS, overall survival;HR, hazard ratio; CI, confidence interval; ND, not determinable;
NR, not reached.
Table 3: Impact of AR/ER and AR/PgR ratios on OS in patients with AR and ER detected both in primary tumor and metastasis (no. 24).
OS (HR) according to best cut-off of the ratios
Primary tumor Metastasis
AR/ER
(cut-off 0.90)
0.33
(95% CI: 0.08 – 1.36)
p = 0.127
0.09
(95% CI: 0.01 - 0.70)
p = 0.022
AR/PgR
(cut-off 0.96)
2.56
(95% CI: 0.56 – 11.72)
p = 0.224
0.53
(95% CI: 0.18 – 1.59)
p = 0.259
Median OS (months) according to AR/ER difference between primary tumor and metastasis
Metastasis
<0.90 ≥0.90
Primary tumor
<0.90 32.4(95% CI: 23.9 - NR)
36.4
(NR) p=0.011
≥0.90 42.2(95% CI: 14.5 - 87.7)
92.0
(95% CI: 89.4 - NR)
AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; OS, overall survival; HR, hazard ratio (AR/ER and AR/PgR ratios <cut-off are the
reference category); CI, confidence interval; ND, not determinable; NR, not reached.
4. Discussion
We previously demonstrated an unfavorable prognostic role
of the AR/ER ratio in different subsets of patients (i.e.,
patients with ductal carcinoma in situ of the breast), inde-
pendently of treatment (i.e., surgery alone or surgery plus
radiotherapy) [12–14]. Similarly, Rangel et al. and Cochrane
et al. reported a poorer prognosis when the AR/ER ratio was
higher in the primary tumor of early BCpatients [9, 10].Then,
considering that data have been reported in the literature
only on the role of AR/ER ratio as unfavorable prognostic
marker in primary tumor of early breast cancer patients,
we performed a study in a different BC population, who
presented disease relapse.We found in the luminal case series
that the AR/ER ratio in primary tumor is not associated with
prognosis and a significantly worse prognosis was observed
when AR/PgR and ER/PgR were high. In both luminal and
overall series the HRs went in the same direction for all
the three ratios even if the statistically significant differences
obtained were not the same. AR/PgR ratio was statistically
different for the luminal case series, whereas ER/PgR ratios
for both. PgR is an independent prognostic biomarker as
previously demonstrated [15] and for this reason it may have
a stronger prognostic impact than AR and ER in the ratios.
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Table 4: Impact of the AR/ER, AR/PgR, and ER/PgR ratios, assessed on primary tumors, on OS in the overall series (no. 159).
Median ratios (range)
AR/ER 0.95 (0 - 95)
AR/PgR 1.59 (0 - 100)
ER/PgR 1.35 (0 - 100)
OS according to best cut-off ratio
Median follow-up: 78 months (range 3-155)
no. deaths/no. patients Median OS (months)(95% CI) HR (95% CI) p
Overall 63/104 62 (50-71) - -
AR/ER
<1.30 53/88 63 (50 - 76) 1.00
≥1.30 10/16 52 (23 - NR) 1.10 (0.56 - 2.16) 0.792
AR/PgR
<1.70 31/51 66 (53 - 84) 1.00
≥1.70 32/53 46 (36 - 65) 1.45 (0.88 - 2.39) 0.147
ER/PgR
<2.00 27/49 81 (62 - 88) 1.00
≥2.00 36/55 46 (36 - 60) 1.90 (1.14 - 3.17) 0.014
AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor;OS, overall survival:HR, hazard ratio; CI, confidence interval; ND, not determinable;
NR, not reached.
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Figure 1: Biomarker detection in breast cancer tissue. Androgen receptor (AR), estrogen receptor (ER), and progesterone receptor (PgR)
expression determined by immunohistochemistry (10X magnification) in primary tumor and metastasis from one patient, with relative
AR/ER, AR/PgR, ER/PgR ratios calculated.
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Moreover an explanation of the cut-off values used for the
ratios could be the different subset of patients analyzed.
The finding of a risk of relapse 10-fold lower for patients
with higher AR/ER values on metastases must be taken with
caution, because it refers to a subgroup of patients whose
AR/ER ratio on primary tumor differs from that of the entire
case series, for the small sample size and the large confidence
intervals. Patients who presented a high AR/ER ratio both in
primary tumor and metastasis had a better prognosis.
5. Conclusion
Although our study was based on a small case series, it had
the advantage of being able to compare primary tumor and
metastatic samples from the same patients, which is fairly
unusual in this setting. In conclusion, our findings indicate
that a prospective study is needed to better clarify the role
of AR/ER ratio in different BC settings (i.e., adjuvant and
metastatic). The relation between AR and PgR has to be
better understood even if our findings suggest that a high
AR/PgR ratio in luminal tumors is prognostically unfavorable
and could be used as an additional risk-stratification marker.
The study of steroid hormone receptors and their relation
with EMT process could lead to a more precise therapeutic
approach.
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